YOU ARE HERE: LAT HomeCollections


Experimental Treatment May Benefit Hepatitis C Patients

New compounds help some control infection. Scientists also get clues into how virus works.

April 18, 2003|From Reuters

WASHINGTON — New experimental compounds may be able to help the body fight off hepatitis C -- an incurable virus that infects millions around the world and causes liver failure and cancer, researchers said Thursday.

The research, done by separate teams in Canada and the United States, also led to discoveries about how hepatitis infects the body -- and how the body fights off infection.

Hepatitis C was identified only in 1989.

It is spread through blood transfusions and the reuse of needles -- including those used for drugs and tattoos.

It infects about 175 million people around the world, including about 4 million in the United States. And many of its sufferers do not know they are even infected.

About 8,000 die every year of hepatitis C in the United States alone.

Viruses such as influenza are eventually cleared by the immune system.

But hepatitis C can stay in the body forever, eluding the various weapons of the immune system.

The national Centers for Disease Control and Prevention in Atlanta says that 75% to 85% of those infected have chronic, or permanent, hepatitis C infection.

Seventy percent of these will develop liver damage leading to cirrhosis and liver cancer.

An antiviral drug called ribavirin, used along with an immune system booster called alpha interferon, can help some patients control hepatitis C infection, but it does not cure it.

"Just a year ago, the hepatitis C virus field had no leads," said Michael Gale, a virologist at the University of Texas Southwestern Medical Center in Dallas who led one of the studies.

"We were totally clueless."

Gale's team and a team led by John Hiscott at McGill University in Montreal found out how the virus deactivates a cell's defenses, so it can stay in the cell virtually forever.

Writing in the journal Science, both teams said they found that the virus can block a cell's production of interferon regulatory factor 3 or IRF3 -- produced by cells to defend against infection and call in more immune system help.

The McGill team found it blocks a second compound called IRF-7.

"This really gives us the first evidence of how it is the virus can cause lifetime infection, as opposed to influenza, which infects you for a week," Gale said in a telephone interview.

Gale's team also discovered that individual cells have their own immune responses, a finding that his team has published in the April issue of the Journal of Virology.

"The whole thing works by IRF3 turning on genes in the human cell that fight off infection. We are going to find out what those genes are, what their products are," Gale said.

This in turn could lead to new ways to battle a number of different viruses, from the AIDS virus to herpes.

In the meantime, two drug companies -- Schering-Plough and the privately owned German company Boehringer Ingelheim -- have developed compounds that they hope will work against hepatitis C.

The work reported in Science was all done in the laboratory, and Gale said the drugs will be difficult to test because no animals are naturally infected with hepatitis C the way humans are.

Los Angeles Times Articles